Endocrine System Exam Questions Answers Related

Review Endocrine System Exam Questions Answers related questions and content

A patient with Alzheimer's disease is taking an acetylcholinesterase inhibitor specifically approved for that indication, primarily because it is quite lipophilic and so enters the CNS well. Which of the following drugs is the patient most likely receiving?

  • A. Donepezil
  • B. Edrophonium
  • C. Neostigmine
  • D. Pyridostigmine
Correct Answer: A

Rationale: The correct answer is A: Donepezil. Donepezil is a lipophilic acetylcholinesterase inhibitor approved for Alzheimer's disease due to its ability to enter the CNS effectively. It enhances cholinergic transmission by inhibiting the enzyme responsible for acetylcholine breakdown. Edrophonium is a short-acting acetylcholinesterase inhibitor used for diagnostic purposes, not for Alzheimer's treatment. Neostigmine and Pyridostigmine are not lipophilic and are primarily used for myasthenia gravis to enhance muscle strength, not for Alzheimer's disease.